Pharmacy refill adherence outperforms self-reported methods in predicting HIV therapy outcome in resource-limited settings

BMC Public Health

Volumn 14, Issue 1, 2014, Pages

  Sangeda, Raphael Z ^a,b   Mosha, Fausta ^b,c   Prosperi, Mattia ^d   Aboud, Said ^a   Vercauteren, Jurgen ^b,e   Camacho, Ricardo J ^b,f   Lyamuya, Eligius F ^a   Van Wijngaerden, Eric ^g   Vandamme, Anne Mieke ^b,f  

^a MUHIMBILI UNIVERSITY OF HEALTH AND ALLIED SCIENCES   (Tanzania)

^b UNIVERSITY OF LEUVEN   (Belgium)

^c MINISTRY OF HEALTH AND SOCIAL WELFARE   (Tanzania)

^d UNIVERSITY OF MANCHESTER   (United Kingdom)

^e JANSSEN RESEARCH FOUNDATION   (Belgium)

^f INSTITUTO DE HIGIENE E MEDICINA TROPICAL   (Portugal)

^g UNIVERSITY HOSPITALS LEUVEN   (Belgium)

Author keywords

Adherence validation; Africa; Antiretroviral; Questionnaires, Sensitivity and specificity, HIV 1; Tanzania

Indexed keywords

ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT;

ADOLESCENT; ADULT; FEMALE; HEALTH CARE PLANNING; HIV INFECTIONS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; ISOLATION AND PURIFICATION; MALE; MEDICATION COMPLIANCE; MIDDLE AGED; PHARMACY; PROCEDURES; PROSPECTIVE STUDY; SELF REPORT; SUPPLY AND DISTRIBUTION; TANZANIA; TREATMENT OUTCOME; UTILIZATION; VIRUS LOAD; YOUNG ADULT;

ADOLESCENT; ADULT; ANTI-HIV AGENTS; FEMALE; HEALTH RESOURCES; HIV INFECTIONS; HIV-1; HUMANS; MALE; MEDICALLY UNDERSERVED AREA; MEDICATION ADHERENCE; MIDDLE AGED; OUTCOME AND PROCESS ASSESSMENT (HEALTH CARE); PHARMACEUTICAL SERVICES; PROSPECTIVE STUDIES; SELF REPORT; TANZANIA; VIRAL LOAD; YOUNG ADULT;

EID: 84907976097     PISSN: None     EISSN: 14712458     Source Type: Journal    
DOI: 10.1186/1471-2458-14-1035     Document Type: Article

References (45)

1. Sensitivity and specificity of using CD4+ measurement and clinical evaluation to determine antiretroviral treatment failure in Thailand. Chaiwarith R, Wachirakaphan C, Kotarathititum W, Praparatanaphan J, Sirisanthana T, Supparatpinyo K, Int J Infect Dis 2007 11 413 416 10.1016/j.ijid.2006.11.003 17331776
2. Immunologic criteria are poor predictors of virologic outcome: implications for HIV treatment monitoring in resource-limited settings. Rawizza HE, Chaplin B, Meloni ST, Eisen G, Rao T, Sankalé J-L, Dieng-Sarr A, Agbaji O, Onwujekwe DI, Gashau W, Nkado R, Ekong E, Okonkwo P, Murphy RL, Kanki PJ, Clin Infect Dis 2011 53 1283 1290 10.1093/cid/cir729 22080121
3. Prognostic value of virological and immunological responses after 6 months of antiretroviral treatment in adults with HIV-1 infection in sub-Saharan Africa. De Luca A, Marazzi MC, Mancinelli S, Ceffa S, Altan AMD, Buonomo E, Prosperi MCF, Pedruzzi B, Noorjehan AM, Scarcella P, Liotta G, Palombi L, J Acquir Immune Defic Syndr 2012 59 236 244 10.1097/QAI.0b013e31824276e9 22327246
4. Adherence to nonnucleoside reverse transcriptase inhibitor-based HIV therapy and virologic outcomes. Nachega JB, Hislop M, Dowdy DW, Chaisson RE, Regensberg L, Maartens G, Ann Intern Med 2007 146 564 573 10.7326/0003-4819-146-8-200704170-00007 17438315
5. Adherence to first-line antiretroviral therapy affects non-virologic outcomes among patients on treatment for more than 12 months in Lusaka, Zambia. Chi BH, Cantrell RA, Zulu I, Mulenga LB, Levy JW, Tambatamba BC, Reid S, Mwango A, Mwinga A, Bulterys M, Saag MS, Stringer JSA, Int J Epidemiol 2009 38 746 756 10.1093/ije/dyp004 19223334
6. Treatment interruptions predict resistance in HIV-positive individuals purchasing fixed-dose combination antiretroviral therapy in Kampala, Uganda. Oyugi JH, Byakika-Tusiime J, Ragland K, Laeyendecker O, Mugerwa R, Kityo C, Mugyenyi P, Quinn TC, Bangsberg DR, AIDS 2007 21 965 971 10.1097/QAD.0b013e32802e6bfa 17457090
7. Preventing HIV antiretroviral resistance through better monitoring of treatment adherence. Bangsberg DR, J Infect Dis 2008 197 Suppl 3 272 S278 18447613
8. The impact of first year adherence to antiretroviral therapy on long-term clinical and immunological outcomes in the DART trial in Uganda and Zimbabwe. Kiwuwa-Muyingo S, Walker AS, Oja H, Levin J, Miiro G, Katabira E, Kityo C, Hakim J, Todd J, Trop Med Int Health 2012 17 584 594 10.1111/j.1365-3156.2012.02974.x 22463596
9. Adherence to highly active antiretroviral therapy assessed by pharmacy claims predicts survival in HIV-infected South African adults. Nachega JB, Hislop M, Dowdy DW, Lo M, Omer SB, Regensberg L, Chaisson RE, Maartens G, J Acquir Immune Defic Syndr 2006 43 78 84 10.1097/01.qai.0000225015.43266.46 16878045
10. A time-to-prescription-refill measure of antiretroviral adherence predicted changes in viral load in HIV. Grossberg R, Zhang Y, Gross R, J Clin Epidemiol 2004 57 1107 1110 10.1016/j.jclinepi.2004.04.002 15528063
11. Antiretroviral therapy adherence and retention in care in middle-income and low-income countries: current status of knowledge and research priorities. Nachega JB, Mills EJ, Schechter M, Curr Opin HIV AIDS 2010 5 70 77 10.1097/COH.0b013e328333ad61 20046150
12. Interventions to increase antiretroviral adherence in sub-Saharan Africa: a systematic review of evaluation studies. Bärnighausen T, Chaiyachati K, Chimbindi N, Peoples A, Haberer J, Newell M-L, Lancet Infect Dis 2011 11 942 951 10.1016/S1473-3099(11)70181-5 22030332
13. Use of pharmacy refill data as a measure of antiretroviral adherence. Grossberg R, Gross R, Curr HIV/AIDS Rep 2007 4 187 191 10.1007/s11904-007-0027-4
14. Self-reported adherence to antiretroviral medications among participants in HIV clinical trials: The AACTG Adherence Instruments. Patient Care Committee & Adherence Working Group of the Outcomes Committee of the Adult AIDS Clinical Trials Group (AACTG). Chesney MA, Ickovics JR, Chambers DB, AIDS Care 2000 12 255 266 10.1080/09540120050042891 10928201
15. Practical and conceptual challenges in measuring antiretroviral adherence. Berg KM, Arnsten JH, J Acquir Immune Defic Syndr 2006 43 Suppl 1 79 S87 17133207
16. Self-report measures of antiretroviral therapy adherence: A review with recommendations for HIV research and clinical management. Simoni JM, Kurth AE, Pearson CR, Pantalone DW, Merrill JO, Frick PA, AIDS Behav 2006 10 227 245 10.1007/s10461-006-9078-6 16783535
17. Utility of self-reported antiretroviral adherence: Comment on Simoni et al. (2006). Wagner GJ, AIDS Behav 2006 10 247 248 10.1007/s10461-006-9122-6 16783536
18. Development and validation of a multidimensional questionnaire assessing non-adherence to medicines. Santa Helena ET, Nemes MI, Eluf-Neto J, Rev Saude Publica 2008 42 764 767 10.1590/S0034-89102008000400025 18709247
19. Adherence to antiretroviral therapy in sub-Saharan Africa and North America: a meta-analysis. Mills EJ, Nachega JB, Buchan I, Orbinski J, Attaran A, Singh S, Rachlis B, Wu P, Cooper C, Thabane L, Wilson K, Guyatt GH, Bangsberg DR, JAMA 2006 296 679 690 10.1001/jama.296.6.679 16896111
20. Factors associated with self-reported adherence to antiretroviral therapy in a Tanzanian setting. Watt MH, Maman S, Golin CE, Earp JA, Eng E, Bangdiwala SI, Jacobson M, AIDS Care 2010 22 381 389 10.1080/09540120903193708 20390519
21. Antiretroviral failure despite high levels of adherence: discordant adherence-response relationship in Botswana. Bisson GP, Rowh A, Weinstein R, Gaolathe T, Frank I, Gross R, J Acquir Immune Defic Syndr 2008 49 107 110 10.1097/QAI.0b013e3181820141 18667926
22. WHO HIV Drug resistance report 2012. [ http://apps.who.int/iris/bitstream/10665/75183/1/9789241503938-eng.pdf ]
23. Simple adherence assessments to predict virologic failure among HIV-infected adults with discordant immunologic and clinical responses to antiretroviral therapy. Goldman JD, Cantrell RA, Mulenga LB, Tambatamba BC, Reid SE, Levy JW, Limbada M, Taylor A, Saag MS, Vermund SH, Stringer JSA, Chi BH, AIDS Res Hum Retroviruses 2008 24 1031 1035 10.1089/aid.2008.0035 18724803
24. Pharmacy adherence measures to assess adherence to antiretroviral therapy: review of the literature and implications for treatment monitoring. McMahon JH, Jordan MR, Kelley K, Bertagnolio S, Hong SY, Wanke CA, Lewin SR, Elliott JH, Clin Infect Dis 2011 52 493 506 10.1093/cid/ciq167 21245156
25. Measurement of adherence in pharmacy administrative databases: a proposal for standard definitions and preferred measures. Hess LM, Raebel MA, Conner DA, Malone DC, Ann Pharmacother 2006 40 1280 1288 10.1345/aph.1H018 16868217
26. Diagnostic value of different adherence measures using electronic monitoring and virologic failure as reference standards. Deschamps AE, De Geest S, Vandamme A-M, Bobbaers H, Peetermans WE, Van Wijngaerden E, AIDS Patient Care STDS 2008 22 735 743 10.1089/apc.2007.0229 18754705
27. Lack of association between retrospectively collected pharmacy refill data and electronic drug monitoring of antiretroviral adherence. Acri TL, TenHave TR, Chapman JC, Bogner HR, Gross R, AIDS Behav 2010 14 748 754 10.1007/s10461-008-9502-1 19089608
28. Viremia and drug resistance among HIV-1 patients on antiretroviral treatment: a cross-sectional study in Soweto, South Africa. El-Khatib Z, Ekstrom AM, Ledwaba J, Mohapi L, Laher F, Karstaedt A, Charalambous S, Petzold M, Katzenstein D, Morris L, Ekström AM, AIDS 2010 24 1679 1687 10.1097/QAD.0b013e32833a097b 20453629
29. Evaluation of the WHO criteria for antiretroviral treatment failure among adults in South Africa. Mee P, Fielding KL, Charalambous S, Churchyard GJ, Grant AD, AIDS 2008 22 1971 1977 10.1097/QAD.0b013e32830e4cd8 18784460
30. Correlates of self-reported nonadherence to antiretroviral therapy in HIV-infected patients: the Swiss HIV Cohort Study. Glass TR, De Geest S, Weber R, Vernazza PL, Rickenbach M, Furrer H, Bernasconi E, Cavassini M, Hirschel B, Battegay M, Bucher HC, J Acquir Immune Defic Syndr 2006 41 385 392 10.1097/01.qai.0000186371.95301.52 16540942
31. R Development Core Team, R: A Language and Environment for Statistical Computing 2012
32. The WEKA data mining software. Hall M, Frank E, Holmes G, Pfahringer B, Reutemann P, Witten IH, ACM SIGKDD Explor Newsl 2009 11 10 10.1145/1656274.1656278
33. Long-term utility of measuring adherence by self-report compared with pharmacy record in a routine clinic setting. Fairley CK, Permana A, Read TRH, HIV Med 2005 6 366 369 10.1111/j.1468-1293.2005.00322.x 16156886
34. Assessing adherence in Thai patients taking combination antiretroviral therapy. Kerr SJ, Avihingsanon A, Putcharoen O, Chetchotisakd P, Layton M, Ubolyam S, Ruxrungtham K, Cooper DA, Phanuphak P, Duncombe C, Int J STD AIDS 2012 23 160 165 10.1258/ijsa.2009.009152 22581867
35. A simple, dynamic measure of antiretroviral therapy adherence predicts failure to maintain HIV-1 suppression. Gross R, Yip B, Lo Re V, Wood E, Alexander CS, Harrigan PR, Bangsberg DR, Montaner JSG, Hogg RS, J Infect Dis 2006 194 1108 1114 10.1086/507680 16991085
36. Measuring adherence to antiretroviral treatment: the role of pharmacy records of drug withdrawals. Gutierrez EB, Sartori AMC, Schmidt AL, Piloto BM, França BB, de Oliveira AS, Pouza AR, Moreno RV, de Melo PC, de Almeida Ribeiro MCS, AIDS Behav 2012 16 1482 1490 10.1007/s10461-012-0168-3 22392157
37. Antiretroviral treatment adherence and its determinants in Sub-Saharan Africa: a prospective study at Yaounde Central Hospital Cameroon. Rougemont M, Stoll BE, Elia N, Ngang P, AIDS Res Ther 2009 6 21 10.1186/1742-6405-6-21 19821997
38. Less than 95% adherence to nonnucleoside reverse-transcriptase inhibitor therapy can lead to viral suppression. Bangsberg DR, Clin Infect Dis 2006 43 939 941 10.1086/507526 16941380
39. Urgent need for coordination in adopting standardized antiretroviral adherence performance indicators. Chalker J, Wagner A, Tomson G, Laing R, Johnson K, Wahlström R, Ross-Degnan D, J Acquir Immune Defic Syndr 2010 53 159 161 10.1097/QAI.0b013e3181befa12 19861899
40. Virological failure and drug resistance in patients on antiretroviral therapy after treatment interruption in Lilongwe, Malawi. Luebbert J, Tweya H, Phiri S, Chaweza T, Mwafilaso J, Hosseinipour MC, Ramroth H, Schnitzler P, Neuhann F, Clin Infect Dis 2012 55 441 448 10.1093/cid/cis438 22573849
41. Plasma drug level validates self-reported adherence but predicts limited specificity for nonadherence to antiretroviral therapy. Balikuddembe R, Kayiwa J, Musoke D, Ntale M, Baveewo S, Waako P, Obua C, ISRN Pharmacol 2012 2012 274978 22530137
42. Validation of self-report and hospital pill count using unannounced home pill count as methods for determination of adherence to antiretroviral therapy. Minzi OMS, Naazneen AS, Tanzan J Health Res 2008 10 84 88 18846785
43. Adherence to antiretroviral therapy assessed by unannounced pill counts conducted by telephone. Kalichman SC, Amaral CM, Stearns H, White D, Flanagan J, Pope H, Cherry C, Cain D, Eaton L, Kalichman MO, J Gen Intern Med 2007 22 1003 1006 10.1007/s11606-007-0171-y 17390095
44. Non-adherence to highly active antiretroviral therapy predicts progression to AIDS. Bangsberg DR, Perry S, Charlebois ED, Clark RA, Roberston M, Zolopa AR, Moss A, AIDS 2001 15 1181 1183 10.1097/00002030-200106150-00015 11416722
45. Clinic Attendance for Medication Refills and Medication Adherence amongst an Antiretroviral Treatment Cohort in Uganda: A Prospective Study. Kunutsor S, Walley J, Katabira E, Muchuro S, Balidawa H, Namagala E, Ikoona E, AIDS Res Treat 2010 2010 872396 21490907